US2019367437A1PendingUtilityA1

Novel Compound Hexadecaphlorethol Isolated From Ishige Okamurae And Use Thereof

Assignee: JEJU NATIONAL UNIV INDUSTRY ACADEMIC COOPERATION FOUNDATIONPriority: Jun 4, 2018Filed: Nov 15, 2018Published: Dec 5, 2019
Est. expiryJun 4, 2038(~11.8 yrs left)· nominal 20-yr term from priority
A23V 2002/00A61K 36/03A23L 33/10C07C 43/295A61P 3/10A23L 2/52A61K 31/09
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are hexadecaphlorethol (HdP), which is a novel compound isolated from Ishige okamurae, and the use thereof in anti-diabetic treatment and exercise performance improvement. The novel compound HdP has the activity of inhibiting α-glucosidase, inducing glucose uptake into differentiated myoblast C2C12 cells, reducing blood glucose levels in zebrafish which have reduced insulin secretion through treatment with alloxan, increasing an intracellular level of calcium ions necessary for muscle contraction and exercise performance in zebrafish, and inducing uptake of glucose, an energy source necessary for muscle contraction, into cells.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A compound of Chemical Formula 1, a hydrate thereof, or a solvate thereof: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The composition comprising the compound of  claim 1  and an excipient. 
     
     
         3 . The composition of  claim 2 , which is in a form of a food composition. 
     
     
         4 . The composition of  claim 2 , which is in a form of a pharmaceutical composition. 
     
     
         5 . A method for improving exercise performance ability, the method comprising:
 administering to a patient in need thereof a therapeutically effective amount of the composition of  claim 2 .   
     
     
         6 . The method of  claim 5 , wherein the composition is in a form of a food composition. 
     
     
         7 . The method of  claim 5 , wherein the composition is in a form of a pharmaceutical composition.

Join the waitlist — get patent alerts

Track US2019367437A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.